Search

Methoxyamine

Glasdegib

Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. … [A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML).

Prenylamine

Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.

Lumiliximab

Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. … Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.

Racepinephrine

It is an active ingredient in oral inhalation over-the-counter products as racepinephrine hydrochloride.

Reposal

Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and anticonvulsant properties. It was used primarily in the treatment of insomnia.

Trilostane

It was withdrawn from the United States market in April 1994.

AS-8112

It has been shown to exert potent antiemetic effects in animal studies and has been investigated for potential medical use. … AS-8112 is a synthetic compound that acts as a selective antagonist at the dopamine receptor subtypes D2 and D3, and the serotonin receptor 5-HT3.

Plant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine

[A245819] Plant-based VLPs offer a number of advantages as compared to other vaccine platforms, including speed and ease of manufacturing and increased immunogenicity. … [L40694] While the concept of plant-based VLPs as vaccines is not new,[A245824] it is a novel approach to COVID-19 vaccination, with previously approved COVID-19 vaccines mostly comprising viral vector

BI-K0376

It is under investigation by Pfizer and has gone through phase I of the clinical trails.